The Zhitong Finance App learned that JD Health (06618) rose more than 7% in the intraday period. As of press release, it had risen 4.51% to HK$27.8, with a turnover of HK$696.94 million.

According to the news, Bank of America Securities released a research report saying that the revenue forecast for JD Health last year was raised from the original forecast of 53 billion yuan to 53.5 billion yuan, which is equivalent to a 14.5% year-on-year increase; the revenue forecast for the second half of last year is expected to remain flat at 26.4 billion yuan year-on-year, mainly due to the outbreak of respiratory diseases in the mainland in the fourth quarter of last year, which is beneficial to the company's drug sales. The bank maintained its adjusted net profit forecast of 55% year-on-year increase to RMB 4.1 billion last year, which is higher than the market forecast of RMB 3.8 billion.

According to a report published by HSBC Research, the recent outbreak of respiratory infections in the mainland has led to continued demand, and strong growth in the health supplement category. The bank raised the company's revenue forecasts for last year, this year and next year by 2% each. Since the revenue outlook is better than expected, it will keep last year's profit forecast unchanged. It also raised non-IFRS net profit by 14% and 3% for this year and next year, respectively. The bank raised its target price to HK$48 and maintained its rating as “buy”.